LRP5 and hepatocellular carcinoma: With the increasing knowledge of the molecular basis of HCC, preclinical investigations and clinical trials have been conducted investigating Wnt/β-catenin signaling targeted interventions, such as with PORCN inhibitor CGX1321, FZD8 decoy receptor OMP-54F28, and LRP5/6 inhibitor Salinomycin (17).